Collectively, this supports that PI3K-AKT–mTOR may represent a key target downstream from HER3, and that CDX-3379 exerts therapeutic effects primarily in PIK3CA wild type HNSCC xenografts. The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.